A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects with Schizophrenia on Stable Doses of Antipsychotic Medication.
Have you been diagnosed with schizophrenia or schizoaffective disorder? Are you experiencing symptoms such as hallucinations, paranoia, confusion, anxiety, lack of interest in communicating with others or trouble sleeping? You may be eligible to participate in a research study at Sharp Mesa Vista Hospital.We are currently enrolling participants for outpatient schizophrenia studies.
This outpatient study is for individuals diagnosed with schizophrenia or schizoaffective disorder. The study will last for approximately 12 weeks and will evaluate the safety, effectiveness and impact on cognitive impairment of an investigational drug (ASP4345) as an add-on treatment to the participant's current antipsychotic medication. Participants will receive either the study drug or a placebo.